STARDUST phase II trial evaluating the eficacy of durvalumab (MEDI4736) as second-line therapy in NSCLC patients receiving concomitant steroids

Authors
Category Systematic review
ConferenceXXVI AIOM National Congress
Year 2024
This article has no abstract
Epistemonikos ID: 7592530dd6c1a664498898cef3d374e07ef9c3b1
First added on: Feb 16, 2026